Cover Image
市場調查報告書

血栓性栓塞症:流行病學、病患人數的市場預測、治療流程、已上市藥物及開發中的藥物分析

Venous thromboembolism: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365166
出版日期 內容資訊 英文 230 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
血栓性栓塞症:流行病學、病患人數的市場預測、治療流程、已上市藥物及開發中的藥物分析 Venous thromboembolism: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 230 Pages
簡介

本報告提供血栓性栓塞症治療藥趨勢調查,市場定義和概要,疾病定義與診斷,治療選擇,處方趨勢,主要的已上市產品簡介,開發平台趨勢等彙整資料。

預測:血栓性栓塞症

  • 摘要整理
  • 市場概要:趨勢
  • 市場定義、調查手法
  • Eliquis (Apixaban)
  • Pradaxa (Dabigatran)
  • Savaysa (edoxaban)
  • Xarelto (rivaroxaban)
  • 主要調查技術

治療:血栓性栓塞症

  • 摘要整理
  • 主要調查技術
  • 疾病定義與診斷
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢

流行病學:血栓性栓塞症

  • 摘要整理
  • 資訊來源、調查手法
  • 預測
  • 流行病學者分析
  • 優勢、規定

已上市藥物:血栓性栓塞症

  • 摘要整理
  • 產品概要
  • 產品簡介:Coumadin
  • 產品簡介:Eliquis
  • 產品簡介:Lovenox
  • 產品簡介:Pradaxa
  • 產品簡介:Savaysa
  • 產品簡介:Xarelto

開發平台:血栓性栓塞症

  • 摘要整理
  • 臨床實驗平台概要
  • 標靶產品簡介
  • 產品簡介 (開發後期):betrixaban

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC12804

The value of the venous thromboembolism (VTE) market is expected to grow rapidly as the approvals of antidotes for the novel oral anticoagulant (NOAC) drugs are secured and physician acceptance of these drugs rises.

This report addresses the following questions:

  • Which patient subgroups and markets will have the largest impact on VTE sales?
  • How will the approval of antidotes affect the uptake of the NOAC drug class?
  • What are the most commonly prescribed therapies for VTE patients?
  • How will Pradaxa's first-to-market antidote affect the market shares of other NOAC molecules?
  • What are the growth drivers and resistors for the NOAC and vitamin K antagonist drug classes during 2015-24?
  • How do the prescribing trends correlate with current recommendations from clinical guidelines?

TABLE OF CONTENTS

FORECAST: VENOUS THROMBOEMBOLISM

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Eliquis (apixaban)
  • 5. Pradaxa (dabigatran)
  • 6. Savaysa (edoxaban)
  • 7. Xarelto (rivaroxaban)
  • 8. Primary Research Methodology

TREATMENT: VENOUS THROMBOEMBOLISM

  • 9. Executive Summary
  • 10. Primary Research Methodology
  • 11. Disease Definition and Diagnosis
  • 12. Country Treatment Trees
  • 13. Current Treatment Options
  • 14. Prescribing Trends

EPIDEMIOLOGY: VENOUS THROMBOEMBOLISM

  • 15. Executive Summary
  • 16. Sources and Methodology
  • 17. Forecast
  • 18. Epidemiologist Insight.
  • 19. Strengths and Limitations

MARKETED DRUGS: VENOUS THROMBOEMBOLISM

  • 20. Executive Summary
  • 21. Product Overview
  • 22. Product profile: Coumadin
  • 23. Product profile: Eliquis
  • 24. Product profile: Lovenox
  • 25. Product profile: Pradaxa
  • 26. Product profile: Savaysa
  • 27. Product profile: Xarelto

PIPELINE: VENOUS THROMBOEMBOLISM

  • 28. Executive Summary
  • 29. Clinical Pipeline Overview
  • 30. Target Product Profile
  • 31. Product profile (late stage): betrixaban
Back to Top